Bayer Hemophilia Awards Program - Research Priorities

Currently, the Program's Research Priorities are focused on hemophilia. They are as follows:

• Clinical studies focusing on treatment modalities for hemophilia, e.g. prophylaxis
• Development of experimental in vitro and in vivo models to evaluate therapeutics for the treatment of bleeding disorders
• Clinical studies focusing on the treatment of adverse events associated with hemophilia, e.g. inhibitor development
• Research into the impact of advancing age on hemophilia patients, including the effect of co-morbidities previously unseen in this patient population
• Discovery or development of new recombinant molecules with potential therapeutic value in bleeding disorders
• New delivery options for these molecules, including gene therapy
• Research to define a molecular basis for inhibitor development in hemophilia
• Health outcomes and quality-of-life research related to hemophilia
• Studies designed to increase the diagnosis, recognition and treatment of hemophilia in underserved areas.

Previous Research

Over the previous five award cycles the Program has provided funding to support several projects in the following areas:

• Aspects of the molecular biology of vWF structure and function and the diagnosis and treatment of vWD
• The function and regulation of platelets and the diagnosis of platelet disorders.

As a result, the Program will not award projects in these areas during this award cycle.

Excluded Research Topics

In order to maintain a focus on hemophilia and bleeding disorders, the Program will not support research focused on:

• Products or technologies licensed or patented by competitors of Bayer Cancer diagnosis or therapy
• AIDS diagnosis or hepatitis therapy except where specifically related to patients with hemophilia and HIV, HCV or HBV
• Cardiovascular disease diagnosis or therapy
• Purely thrombotic disorders.